A Phase III, Multicenter, Randomized Study of ABX Plus Cisplatin (AP) Versus Gemcitabine Plus Cisplatin (GP) as First-Line Treatment in Patients With Advanced Triple-Negative Breast Cancer
Latest Information Update: 25 Apr 2022
At a glance
- Drugs Cisplatin (Primary) ; Paclitaxel (Primary) ; Gemcitabine
- Indications Advanced breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- Acronyms GAP trial
- 20 Apr 2022 Status changed from active, no longer recruiting to completed.
- 25 Nov 2020 New trial record